DUBLIN, July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 24, 2024 to discuss the company's second quarter financial results.The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcas ...

The market expects Alkermes (ALKS) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the s ...

— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested —— ALKS 2680 Was Generally Well Tolerated at All Doses Tested —— Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing —DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept stu ...

– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations –– Findings From In-Depth Qualitative Patient Interviews on the Burden of Narcolepsy Will Also Be Presented –DUBLIN, May 28, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies ...

As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised for a resurgence. Breakthroughs in personalized medicine and gene editing technologies are driving biotech forward.The global biotechnology market was valued at $1.0 trillion in 2022 and is projected to reach $3.6 trillion by 2032. Increasing demand for personalized medicine and advancements in genetic engineering will d ...

Alkermes plc (ALKS) reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had reported adjusted earnings of 18 per share in the year-ago quarter.ALKS’ revenues of $350.4 million rose 21.8% from the year-ago quarter’s level owing to the strong performance of its proprietary products portfolio. The top line, however, missed the Zacks Consensus Estimate of $360 million.Quarter in DetailAlkermes deri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1007018 (State or other jurisdiction of incorporation or o ...

Alkermes plc (NASDAQ:ALKS) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Blair Jackson - Chief Operating Officer Todd Nichols - Chief Commercial Officer Richard Pops - Chief Executive Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Umer Raffat - Evercore ISI Jason Gerberry - Bank of America Uy Ear - Mizuho Securities Jessica ...

Alkermes (ALKS) reported $350.37 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 21.8%. EPS of $0.44 for the same period compares to $0.01 a year ago.The reported revenue represents a surprise of -2.75% over the Zacks Consensus Estimate of $360.26 million. With the consensus EPS estimate being $0.59, the EPS surprise was -25.42%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stree ...

First Quarter 2024 Financial Results & Business Update May 1, 2024 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc’s (the “Company”) expectations with respect to its current and future financial, commercial and operating performance, business plans or p ...